Paraoxonase Activity in Two Healthy Populations with Differing Rates of Coronary Heart Disease
Overview
Authors
Affiliations
Background: The rate of coronary heart disease is over three-fold greater in Belfast than in Toulouse and the excess risk cannot be totally explained by 'classical' risk factors such as total cholesterol, LDL-cholesterol, smoking, etc.
Design: The effect of the human serum paraoxonase (PON1) 192-genetic polymorphism on plasma lipid and lipoprotein concentrations and on PON1 activity and concentration was investigated in 186 randomly selected healthy subjects from Toulouse and 165 from Belfast.
Results: The frequency of the R allele of PON1, which has been related to the risk of coronary heart disease, was significantly higher in Belfast (0.33) than in Toulouse (0.24; chi2 = 7.229, P = 0.0072). Subjects from Belfast also had significantly higher serum cholesterol, triglycerides, LDL-cholesterol, and apolipoprotein B, and significantly lower HDL-cholesterol and apolipoprotein A1, but these lipoprotein parameters were independent of the PON1 192-polymorphisms. PON1 activity towards paraoxon was significantly higher in the Belfast population than in Toulouse (median values: 179.7 vs. 129.4 nmol min-1 mL-1 serum, respectively; P < 0.05), which is consistent with our finding of a greater prevalence of the R allele. The median serum concentration of PON1 was 56.3 microgram mL-1 in Belfast, which was significantly lower (P < 0.005) than the level of 71 microgram mL-1 in Toulouse.
Conclusions: Our results thus provide further support for the hypothesis that populations at increased CHD risk have diminished serum PON1 concentration and an increased prevalence of the R allele of PON1. They are also consistent with reports that the ability of PON1 to hydrolyse paraoxon is inversely related to its capacity to hydrolyse lipid-peroxides, and thus to its antiatherogenic action.
Cho K, Baek S, Nam H, Bahuguna A, Lopez-Gonzalez L, Rodriguez-Cortina I Curr Issues Mol Biol. 2024; 46(1):409-429.
PMID: 38248328 PMC: 10813917. DOI: 10.3390/cimb46010026.
HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.
Linton M, Yancey P, Tao H, Davies S Circ Res. 2023; 132(11):1521-1545.
PMID: 37228232 PMC: 10213997. DOI: 10.1161/CIRCRESAHA.123.321563.
Kuchta A, Konopacka A, Waleron K, Viapiana A, Wesolowski M, Dabkowski K Cardiol J. 2019; 28(4):534-542.
PMID: 30912576 PMC: 8277009. DOI: 10.5603/CJ.a2019.0028.
Kortas J, Kuchta A, Prusik K, Prusik K, Ziemann E, Labudda S Biogerontology. 2017; 18(4):517-524.
PMID: 28229255 PMC: 5514214. DOI: 10.1007/s10522-017-9681-0.
Kuchta A, Strzelecki A, Cwiklinska A, Toton M, Gruchala M, Zdrojewski Z Oxid Med Cell Longev. 2015; 2015:5136937.
PMID: 26697134 PMC: 4677230. DOI: 10.1155/2016/5136937.